Moreover, in an APP/PS1/tau mouse model of AD, a current study has suggested that lixisenatide (i.e., glucagon-like peptide 1 receptor agonists) can reduce neuroinflammation, NFTs, and amyloid plaques [282]. The gene discussed is MAPT; the disease is Alzheimer disease.